The trial enrolled 1,841 patients and measured DFS, with safety, OS, and quality of life as secondary endpoints.
Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...
Eftilagimod alfa and Keytruda with radiotherapy improved tumor hyalinization/fibrosis rates in resectable soft tissue sarcoma, surpassing the trial's primary endpoint. The combination therapy achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results